BEBT-109, A PAN-MUTANT-SELECTIVE EGFR INHIBITOR WITH POTENT ANTITUMOR ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

EGFR mutation-positive NSCLC tumors are highly heterogeneous, therefore, exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical Recreation Room Products practice.Compared with osimertinib, BEBT-109 shows more sensitive and extensive antitumor activity in EGFR mutant NSCLC, while sparing wild-type EGFR cell

read more




The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans

Intranasal delivery provides a practical, noninvasive method of bypassing the blood-brain barrier (BBB) in order to deliver therapeutic agents to the brain.This method allows drugs that do not cross the BBB to be delivered to the central nervous system in a few minutes.With this technology, it will be possible to eliminate systemic administration a

read more